- Home
- / Athenex
Athenex
Stock Price
$0
2023-07-26
Market Capitalization
$2.3 M
2023-07-26
Revenue
$102.8 M
FY, 2022
Athenex Summary
Company Summary
- Overview
- Athenex is a biopharmaceutical company dedicated to the discovery and commercialization of therapies for the treatment of cancer. It operates medical technology innovation centers and a manufacturing supply chain. The company delivers proprietary medical technologies, including small molecule, biologic, and cellular therapies.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Buffalo, NY, US | view all locations
- Website
- https://www.athenex.com/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
11 locations detected
Buffalo, NY HQ
United States
Conventus, 1001 Main St #600
Clarence, NY
United States
11342 Main St
Cranford, NJ
United States
20 Commerce Dr #100
Houston, TX
United States
6200 Savoy Dr #1200
Schaumburg, IL
United States
10 N Martingale Rd #230
CABA
Argentina
piso 12, Carlos Pellegrini 713
Athenex Financials
Summary Financials
- Revenue (FY, 2022)
- $102.8M
- Gross profit (FY, 2022)
- $26.7M
- Net income (FY, 2022)
- ($104.4M)
- Cash (FY, 2022)
- $30.4M
- EBIT (FY, 2022)
- ($70.0M)
- Enterprise value
- $14.3M